嵌合抗原受体 T 细胞疗法已用于治疗各种 B 细胞恶性肿瘤。然而，由于实体瘤的肿瘤间以及肿瘤内异质性和免疫抑制微环境，将这种治疗效果转化为治疗实体瘤一直具有挑战性。手术、放疗、局部消融和局部药物输送等局部干预措施可以通过改善肿瘤浸润和减少全身毒性来增强实体瘤中的嵌合抗原受体 T 细胞治疗。此外，消融和放疗已被证明可以通过远隔效应（重新）激活全身免疫反应，并在物理、细胞和化学水平上重新编程肿瘤微环境。本综述强调了克服嵌合抗原受体 T 细胞疗法障碍的组合方法的潜在协同作用，并总结了可能为新治疗方案铺平道路的最新研究。© 2024。作者。

Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell malignancies. However, translating this therapeutic effect to treat solid tumors has been challenging because of their inter-tumoral as well as intratumoral heterogeneity and immunosuppressive microenvironment. Local interventions, such as surgery, radiotherapy, local ablation, and locoregional drug delivery, can enhance chimeric antigen receptor T cell therapy in solid tumors by improving tumor infiltration and reducing systemic toxicities. Additionally, ablation and radiotherapy have proven to (re-)activate systemic immune responses via abscopal effects and reprogram the tumor microenvironment on a physical, cellular, and chemical level. This review highlights the potential synergy of the combined approaches to overcome barriers of chimeric antigen receptor T cell therapy and summarizes recent studies that may pave the way for new treatment regimens.© 2024. The Author(s).